IRVINE, Calif., Sept. 5, 2012 /PRNewswire/ -- AtheroNova
Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the
research and development of compounds to regress atherosclerotic
plaque, will be a presenting company at the Rodman & Renshaw
14th Annual Healthcare and Global Investment Conference
to be held in New York City from
September 9 -11, 2012 at the
Waldorf-Astoria. Mark
Selawski, CFO of AtheroNova, will present at 3:15pm ET on Tuesday,
September 11.
Mr. Selawski will discuss exciting near term milestones for
AHRO-001, the Company's lead compound for the regression of
atherosclerotic plaque, as well as the Company's pipeline and
development plans.
In addition to the presentation, Mr. Selawski will be available
to meet with analysts, industry executives and investors in
one-on-one meetings. Those interested in meeting with Mr.
Selawski for a one-on-one discussion during the Conference are
encouraged to contact the Company directly at
info@atheronova.com.
About AtheroNova
AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova
Operations, Inc., is an early stage biotech company focused on
discovery, research, development and licensing of novel compounds
to reduce or regress atherosclerotic plaque deposits. The
Company's focus on compounds to reduce or eliminate atherosclerotic
plaque deposits addresses the most lucrative segments of the
multi-billion dollar prescription drug market: cardiovascular
disease and stroke prevention. www.AtheroNova.com
Forward-Looking Statements
Except for historical information contained herein, the
statements in this release are forward-looking and made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are inherently
unreliable and actual results may differ materially. Examples of
forward looking statements in this news release include statements
regarding the Company's pipeline, milestones and the development of
applications for AtheroNova's technology. Factors which could cause
actual results to differ materially from these forward-looking
statements include such factors as significant fluctuations in
expenses associated with clinical trials, failure to secure
additional financing, the inability to complete regulatory filings
with the Food and Drug Administration, the introduction of
competing products, or management's ability to attract and maintain
qualified personnel necessary for the development and
commercialization of its planned products, and other information
that may be detailed from time to time in AtheroNova's filings with
the United States Securities and Exchange Commission. AtheroNova
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE AtheroNova Inc.